Hollow fiber-combined glucose-responsive gel technology as an in vivo electronics-free insulin delivery system

[1]  R. Dahlstrom,et al.  Challenges and opportunities , 2021, Foundations of a Sustainable Economy.

[2]  Akira Matsumoto,et al.  Microneedle‐Array Patch Fabricated with Enzyme‐Free Polymeric Components Capable of On‐Demand Insulin Delivery , 2018, Advanced Functional Materials.

[3]  Dan Dan Zhu,et al.  Insulin delivery systems combined with microneedle technology. , 2018, Advanced drug delivery reviews.

[4]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[5]  Y. Miyahara,et al.  Synthetic “smart gel” provides glucose-responsive insulin delivery in diabetic mice , 2017, Science Advances.

[6]  T. Hansen,et al.  Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777–783 , 2017, Diabetes Care.

[7]  B. Zinman,et al.  Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial , 2017, Diabetes Care.

[8]  T. Bailey,et al.  The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System , 2015, Diabetes technology & therapeutics.

[9]  Benjamin C. Tang,et al.  Managing diabetes with nanomedicine: challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[10]  Akira Matsumoto,et al.  A synthetic approach toward a self-regulated insulin delivery system. , 2012, Angewandte Chemie.

[11]  Roman Hovorka,et al.  Closed-loop insulin delivery: towards improved diabetes care. , 2012, Discovery medicine.

[12]  George Dailey,et al.  Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. , 2010, The New England journal of medicine.

[13]  Akira Matsumoto,et al.  A totally synthetic glucose responsive gel operating in physiological aqueous conditions. , 2010, Chemical communications.

[14]  Michael E. Miller,et al.  The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study , 2010, BMJ : British Medical Journal.

[15]  A. Berghold,et al.  Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis , 2008, Diabetologia.

[16]  J. Pickup,et al.  Are insulin pumps underutilized in type 1 diabetes? Yes. , 2006, Diabetes care.

[17]  Virginia Valentine,et al.  Counterpoint: Are Insulin Pumps Underutilized in Type 1 Diabetes? No , 2006, Diabetes Care.

[18]  Jean-Paul Cristol,et al.  Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. , 2006, JAMA.

[19]  R. Hovorka.  Continuous glucose monitoring and closed‐loop systems , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[20]  J. Gobburu,et al.  Population Pharmacokinetic–Pharmacodynamic Modeling of Subcutaneous and Pulmonary Insulin in Rats , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[21]  Akira Matsumoto,et al.  Glucose-responsive polymer gel bearing phenylborate derivative as a glucose-sensing moiety operating at the physiological pH. , 2004, Biomacromolecules.

[22]  Akira Matsumoto,et al.  Swelling and Shrinking Kinetics of Totally Synthetic, Glucose-Responsive Polymer Gel Bearing Phenylborate Derivative as a Glucose-Sensing Moiety , 2004 .

[23]  K. Kataoka,et al.  Glucose-responsive polymer bearing a novel phenylborate derivative as a glucose-sensing moiety operating at physiological pH conditions. , 2003, Biomacromolecules.

[24]  J. Weissberg-Benchell,et al.  Insulin pump therapy: a meta-analysis. , 2003, Diabetes care.

[25]  T. Miyata,et al.  Biomolecule-sensitive hydrogels. , 2002, Advanced drug delivery reviews.

[26]  B. Zinman,et al.  Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. , 2001, Diabetes care.

[27]  L. Andersen,et al.  Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[28]  T. Okano,et al.  Totally Synthetic Polymer Gels Responding to External Glucose Concentration: Their Preparation and Application to On−Off Regulation of Insulin Release , 1998 .

[29]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[30]  D. Rogers,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus , 1994 .

[31]  D. Kelley,et al.  Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. , 1992, The New England journal of medicine.

[32]  J. Schlichtkrull,et al.  [M-VALUE, AN INDEX FOR BLOOD SUGAR CONTROL IN DIABETICS]. , 1964, Ugeskrift for laeger.

[33]  F. Ovalle,et al.  Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes , 2009 .

[34]  T. Md.  Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin , 2004, Diabetologia.

[35]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[36]  Kinam Park,et al.  Environment-sensitive hydrogels for drug delivery. , 2001, Advanced drug delivery reviews.

[37]  V. Kadirkamanathan.  The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT) , 1998, Diabetologia.